open access

Vol 64, No 5 (2013)
Original papers
Published online: 2013-11-01
Submitted: 2013-11-04
Accepted: 2013-11-04
Get Citation

Interferon alpha and rapamycin inhibit the growth of pheochromocytoma PC12 line in vitro

Ewelina Motylewska, Hanna Lawnicka, Magdalena Kowalewicz-Kulbat, Paulina Sicinska, Agata Niedziela, Gabriela Melen-Mucha, Henryk Stepien
DOI: 10.5603/EP.2013.0020
·
Endokrynologia Polska 2013;64(5):368-374.

open access

Vol 64, No 5 (2013)
Original papers
Published online: 2013-11-01
Submitted: 2013-11-04
Accepted: 2013-11-04

Abstract

Introduction: Pheochromocytomas are benign or malignant neuroendocrine tumours. The unsatisfactory efficacy of the traditional
therapeutic methods for patients with metastatic disease results in a continuing search for more effective and targeted agents. Due to the
increased vascularisation of these tumours, inhibitors of angiogenesis could be potentially a new group of drugs in pheochromocytoma/paraganglioma therapy.

Material and methods: The aim of this study was to evaluate the influence of angiomodulators: VEGF (vascular endothelial growth factor)
and five endogenous and exogenous antiangiogenic compounds (endostatin; IFN-alpha [interferon alpha]; rapamycin — mTOR [mammalian
target of rapamycin] inhibitor; JV1-36 and SU5416 (semaxinib]) on the growth of rat pheochromocytoma PC12 cell line.

Results: IFN-alpha (105 U/mL) strongly inhibited PC12 growth in a 72 h culture, increasing apoptosis and arresting the cell cycle. Rapamycin
in a wide range of concentrations (10-5 to 10-8 M) induced a slight inhibitory effect on PC12 viability and decreased cell proliferation at the
concentration of 10-5 M. VEGF, endostatin and JV1-36 did not influence the growth of PC12.

onclusions: The study has shown for the first time that IFN-a inhibited the growth of pheochromocytoma PC12 line and confirmed the
inhibitory action of rapamycin on these cells. The results suggest that IFN-alpha and mTOR inhibitors could be potentially effective in the
therapy of malignant pheochromocytoma, and encourage further study in this field.

(Endokrynol Pol 2013; 64 (5): 368–374)

Abstract

Introduction: Pheochromocytomas are benign or malignant neuroendocrine tumours. The unsatisfactory efficacy of the traditional
therapeutic methods for patients with metastatic disease results in a continuing search for more effective and targeted agents. Due to the
increased vascularisation of these tumours, inhibitors of angiogenesis could be potentially a new group of drugs in pheochromocytoma/paraganglioma therapy.

Material and methods: The aim of this study was to evaluate the influence of angiomodulators: VEGF (vascular endothelial growth factor)
and five endogenous and exogenous antiangiogenic compounds (endostatin; IFN-alpha [interferon alpha]; rapamycin — mTOR [mammalian
target of rapamycin] inhibitor; JV1-36 and SU5416 (semaxinib]) on the growth of rat pheochromocytoma PC12 cell line.

Results: IFN-alpha (105 U/mL) strongly inhibited PC12 growth in a 72 h culture, increasing apoptosis and arresting the cell cycle. Rapamycin
in a wide range of concentrations (10-5 to 10-8 M) induced a slight inhibitory effect on PC12 viability and decreased cell proliferation at the
concentration of 10-5 M. VEGF, endostatin and JV1-36 did not influence the growth of PC12.

onclusions: The study has shown for the first time that IFN-a inhibited the growth of pheochromocytoma PC12 line and confirmed the
inhibitory action of rapamycin on these cells. The results suggest that IFN-alpha and mTOR inhibitors could be potentially effective in the
therapy of malignant pheochromocytoma, and encourage further study in this field.

(Endokrynol Pol 2013; 64 (5): 368–374)

Full Text:

View HTML
Get Citation

Keywords

pheochromocytoma; interferon alpha; rapamycin; antiangiogenic factors; PC12 line

About this article
Title

Interferon alpha and rapamycin inhibit the growth of pheochromocytoma PC12 line in vitro

Journal

Endokrynologia Polska

Issue

Vol 64, No 5 (2013)

Pages

368-374

Published online

2013-11-01

DOI

10.5603/EP.2013.0020

Bibliographic record

Endokrynologia Polska 2013;64(5):368-374.

Keywords

pheochromocytoma
interferon alpha
rapamycin
antiangiogenic factors
PC12 line

Authors

Ewelina Motylewska
Hanna Lawnicka
Magdalena Kowalewicz-Kulbat
Paulina Sicinska
Agata Niedziela
Gabriela Melen-Mucha
Henryk Stepien

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl